应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
TY Tri-Continental Corp
休市中 10-09 16:00:00 EDT
34.78
+0.31
+0.90%
盘后
34.78
+0.00
0.00%
19:30 EDT
最高
34.90
最低
34.64
成交量
3.56万
今开
34.64
昨收
34.47
日振幅
0.74%
总市值
18.50亿
流通市值
18.50亿
总股本
5,319万
成交额
123.83万
换手率
0.07%
流通股本
5,319万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
同源康医药-B午后涨超5% 齐鲁制药获TY-9591独家商业化授权
新浪港股 · 07-27
同源康医药-B午后涨超5% 齐鲁制药获TY-9591独家商业化授权
汇宇制药：与同源康就“TY - 9591”产品协议纠纷互诉
智通财经 · 07-22
汇宇制药：与同源康就“TY - 9591”产品协议纠纷互诉
同源康医药(02410)自主研发TY-3002单药展现卓越减重疗效，引领下一代口服GLP-1R小分子创新
智通财经 · 04-16
同源康医药(02410)自主研发TY-3002单药展现卓越减重疗效，引领下一代口服GLP-1R小分子创新
港股异动 | 同源康医药-B(02410)早盘一度涨超40% TY-9591关键II期临床试验研究者数据显示达到研究预期
智通财经 · 2025-03-10
港股异动 | 同源康医药-B(02410)早盘一度涨超40% TY-9591关键II期临床试验研究者数据显示达到研究预期
同源康医药TY-9591II期临床试验达到研究预期
财中社 · 2025-03-09
同源康医药TY-9591II期临床试验达到研究预期
【同源康医药-B(02410.HK)：TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验研究者数据显示达到研究预期，具有统计学显著意义和重大临床获益】同源康医药-B(02410.HK)公布，公司自主研发的TY-9591(商品名：卡达沙®)对比奥希替尼(商品名：泰瑞沙®)作为一线治疗EGFR突变肺癌脑转移的关键 II期临床试验根据研究者数据显示具有统计学显著意义和重大临床获益。主要研究终点颅内客观缓解率(iORR)达到预期目的，TY-9591对比奥希替尼显示出统计学显著意义和临床意义的明显改善，无论在全人群还是在不同亚组人群(包括基因分型、颅内病灶个数、ECOG评分等)中均具有明显统计学差异。
金融界 · 2025-03-09
【同源康医药-B(02410.HK)：TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验研究者数据显示达到研究预期，具有统计学显著意义和重大临床获益】同源康医药-B(02410.HK)公布，公司自主研发的TY-9591(商品名：卡达沙®)对比奥希替尼(商品名：泰瑞沙®)作为一线治疗EGFR突变肺癌脑转移的关键 II期临床试验根据研究者数据显示具有统计学显著意义和重大临床获益。主要研究终点颅内客观缓解率(iORR)达到预期目的，TY-9591对比奥希替尼显示出统计学显著意义和临床意义的明显改善，无论在全人群还是在不同亚组人群(包括基因分型、颅内病灶个数、ECOG评分等)中均具有明显统计学差异。
同源康医药-B(02410)：TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验研究者数据显示达到研究预期，具有统计学显著意义和重大临床获益
智通财经 · 2025-03-09
同源康医药-B(02410)：TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验研究者数据显示达到研究预期，具有统计学显著意义和重大临床获益
港股异动 | 同源康医药-B(02410)午后涨近20%再创新高 核心产品TY-959已获得IND批准
智通财经 · 2024-11-26
港股异动 | 同源康医药-B(02410)午后涨近20%再创新高 核心产品TY-959已获得IND批准
加载更多
公司概况
公司名称：
Tri-Continental Corp
所属市场：
NYSE
上市日期：
--
主营业务：
Tri-Continental Corporation是一家多元化基金。该基金根据1940年《投资公司法》及其修订版（1940年法案）注册为封闭式管理投资公司。
发行价格：
--
{"stockData":{"symbol":"TY","market":"US","secType":"STK","nameCN":"Tri-Continental Corp","latestPrice":34.78,"timestamp":1791576000000,"preClose":34.47,"halted":0,"volume":35556,"hourTrading":{"tag":"盘后","latestPrice":34.78,"preClose":34.78,"latestTime":"19:30 EDT","volume":4,"amount":139.12,"timestamp":1791588606137,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.008993327531186606,"floatShares":53189373,"shares":53189373,"eps":6.211458,"marketStatus":"休市中","change":0.31,"latestTime":"10-09 16:00:00 EDT","open":34.64,"high":34.895,"low":34.64,"amount":1238345.79024,"amplitude":0.007398,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":6.211458,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":34.47,"dividendRate":0.107136,"preHourTrading":{"tag":"盘前","latestPrice":35.59,"preClose":34.47,"latestTime":"08:52 EDT","volume":2,"amount":70.06,"timestamp":1791550362283,"change":1.12,"changeRate":0.032492,"amplitude":0.032492},"postHourTrading":{"tag":"盘后","latestPrice":34.78,"preClose":34.78,"latestTime":"19:30 EDT","volume":4,"amount":139.12,"timestamp":1791588606137,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.0597281859613594},"requestUrl":"/m/hq/s/TY","defaultTab":"news","newsList":[{"id":"2654972091","title":"同源康医药-B午后涨超5% 齐鲁制药获TY-9591独家商业化授权","url":"https://stock-news.laohu8.com/highlight/detail?id=2654972091","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654972091?lang=zh_cn&edition=full","pubTime":"2026-07-27 13:12","pubTimestamp":1785129120,"startTime":"0","endTime":"0","summary":" 同源康医药-B盘中涨超6%，截至发稿，股价上涨5.39%，现报7.23港元，成交额1757.17万港元。 齐鲁制药获同源康医药肺癌靶向创新药TY-9591独家商业化授权，齐鲁制药还将对同源康医药进行股权投资。 公开资料显示，TY-9591是同源康医药自主研发的新一代高选择性不可逆EGFR-TKI，也是国内差异化优势突出的肺癌靶向新药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-27/doc-inikfnpf3106086.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01477","BK1574","09939","02410","159938","TY","BK1515","BK1191","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653755464","title":"汇宇制药：与同源康就“TY - 9591”产品协议纠纷互诉","url":"https://stock-news.laohu8.com/highlight/detail?id=2653755464","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653755464?lang=zh_cn&edition=full","pubTime":"2026-07-22 17:21","pubTimestamp":1784712063,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["TY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627829301","title":"同源康医药(02410)自主研发TY-3002单药展现卓越减重疗效，引领下一代口服GLP-1R小分子创新","url":"https://stock-news.laohu8.com/highlight/detail?id=2627829301","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2627829301?lang=zh_cn&edition=full","pubTime":"2026-04-16 17:07","pubTimestamp":1776330475,"startTime":"0","endTime":"0","summary":"近日，同源康医药宣布正式提名其自主研发的下一代口服小分子GLP-1R激动剂TY-3002为临床前候选化合物。在反映临床潜力的hGLP-1R饮食诱导肥胖小鼠头对头试验中，TY-3002展现出了优越的减重效果。治疗21天后，TY-3002组小鼠的体重极显著地下降了-31.51%，而同等剂量的Orforglipron组降幅为-22.82%。新一代GLP-1R小分子TY-3002的提名，充分彰显了同源康医药领先的分子设计能力，也为全球下一代口服减重药物领域开启了新的竞争格局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429400.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1515","BK1574","BK4144","GLP","159938","09939","02410","BK4590","TY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518255540","title":"港股异动 | 同源康医药-B(02410)早盘一度涨超40% TY-9591关键II期临床试验研究者数据显示达到研究预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2518255540","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518255540?lang=zh_cn&edition=full","pubTime":"2025-03-10 09:34","pubTimestamp":1741570495,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B早盘一度涨超40%，截至发稿，涨36.93%，报41.9港元，成交额330万港元。消息面上，3月9日，同源康医药-B发布公告，公司自主研发的TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验根据研究者数据显示具有统计学显著意义和重大临床获益。公司计划于近期向国家药品监督管理局药品审评中心提交NDA上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","159938","BK1574","BK1141","09939","BK1583","BK1161","TY","03347","02410","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518885407","title":"同源康医药TY-9591II期临床试验达到研究预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2518885407","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518885407?lang=zh_cn&edition=full","pubTime":"2025-03-09 19:30","pubTimestamp":1741519833,"startTime":"0","endTime":"0","summary":"3月9日，同源康医药-B（02410）发布公告，宣布其自主研发的TY-9591（商品名：卡达沙?）在对比奥希替尼（商品名：泰瑞沙?）作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验中，达到了研究预期，具有统计学显著意义和重大临床获益。试验结果显示，主要研究终点即颅内客观缓解率(iORR)达到了预期目的，TY-9591在全人群及不同亚组人群中均显示出明显的统计学差异。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503093340520562.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503093340520562.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1161","BK1574","TY","BK1141","09939","BK1515","BK1576","03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518684402","title":"【同源康医药-B(02410.HK)：TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验研究者数据显示达到研究预期，具有统计学显著意义和重大临床获益】同源康医药-B(02410.HK)公布，公司自主研发的TY-9591(商品名：卡达沙®)对比奥希替尼(商品名：泰瑞沙®)作为一线治疗EGFR突变肺癌脑转移的关键 II期临床试验根据研究者数据显示具有统计学显著意义和重大临床获益。主要研究终点颅内客观缓解率(iORR)达到预期目的，TY-9591对比奥希替尼显示出统计学显著意义和临床意义的明显改善，无论在全人群还是在不同亚组人群(包括基因分型、颅内病灶个数、ECOG评分等)中均具有明显统计学差异。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518684402","media":"金融界","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518684402?lang=zh_cn&edition=full","pubTime":"2025-03-09 19:12","pubTimestamp":1741518744,"startTime":"0","endTime":"0","summary":"同源康医药-B(02410.HK)公布，公司自主研发的TY-9591(商品名：卡达沙®)对比奥希替尼(商品名：泰瑞沙®)作为一线治疗EGFR突变肺癌脑转移的关键 II期临床试验根据研究者数据显示具有统计学显著意义和重大临床获益。主要研究终点颅内客观缓解率(iORR)达到预期目的，TY-9591对比奥希替尼显示出统计学显著意义和临床意义的明显改善，无论在全人群还是在不同亚组人群(包括基因分型、颅内病灶个数、ECOG评分等)中均具有明显统计学差异。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/09191248615055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1576","BK1583","BK1141","02410","BK1515","BK1161","BK1574","TY","03347","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518440289","title":"同源康医药-B(02410)：TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验研究者数据显示达到研究预期，具有统计学显著意义和重大临床获益","url":"https://stock-news.laohu8.com/highlight/detail?id=2518440289","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518440289?lang=zh_cn&edition=full","pubTime":"2025-03-09 19:07","pubTimestamp":1741518432,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同源康医药-B(02410)公布，公司自主研发的TY-9591(商品名：卡达沙®)对比奥希替尼(商品名：泰瑞沙®)作为一线治疗EGFR突变肺癌脑转移的关键 II期临床试验根据研究者数据显示具有统计学显著意义和重大临床获益。主要研究终点颅内客观缓解率(iORR)达到预期目的，TY-9591对比奥希替尼显示出统计学显著意义和临床意义的明显改善，无论在全人群还是在不同亚组人群(包括基因分型、颅内病灶个数、ECOG评分等)中均具有明显统计学差异。公司计划于近期向国家药品监督管理局药品审评中心(CDE)提交NDA (New Drug Application)上市申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","159938","02410","BK1574","BK1141","BK1576","09939","BK1515","BK1583","TY","03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2486336041","title":"港股异动 | 同源康医药-B(02410)午后涨近20%再创新高 核心产品TY-959已获得IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2486336041","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2486336041?lang=zh_cn&edition=full","pubTime":"2024-11-26 14:57","pubTimestamp":1732604248,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B午后涨近20%，高见38.5港元，创上市新高，较招股价12.1港元已涨超2倍。截至发稿，涨11.52%，报34.85港元，成交额1189.25万港元。据悉，公司已建立由11款候选药物组成的管线，包括2个低风险产品TY-9591、TY-302，5款创新临床产品，4款处于临床前阶段的产品。值得注意的是，公司已获得国家药监局对其核心产品TY-9591的II期和III期临床试验的IND批准，同时正在进行产品TY-302和TY-2136b的关键临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1215901.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","09939","02410","159938","TY","BK1515"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://columbiathreadneedleus.com","stockEarnings":[{"period":"1week","weight":0.014},{"period":"1month","weight":-0.0105},{"period":"3month","weight":-0.0203},{"period":"6month","weight":0.06},{"period":"1year","weight":0.0164},{"period":"ytd","weight":0.0649}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.0313},{"period":"6month","weight":0.1459},{"period":"1year","weight":0.16},{"period":"ytd","weight":0.1417}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Tri-Continental Corporation是一家多元化基金。该基金根据1940年《投资公司法》及其修订版（1940年法案）注册为封闭式管理投资公司。","yearOnYearQuotes":[{"month":1,"riseRate":0.586957,"avgChangeRate":-0.00053},{"month":2,"riseRate":0.565217,"avgChangeRate":0.005029},{"month":3,"riseRate":0.478261,"avgChangeRate":-0.002186},{"month":4,"riseRate":0.638298,"avgChangeRate":0.016109},{"month":5,"riseRate":0.702128,"avgChangeRate":0.016997},{"month":6,"riseRate":0.425532,"avgChangeRate":-0.008909},{"month":7,"riseRate":0.595745,"avgChangeRate":0.012041},{"month":8,"riseRate":0.595745,"avgChangeRate":0.005554},{"month":9,"riseRate":0.404255,"avgChangeRate":-0.012957},{"month":10,"riseRate":0.638298,"avgChangeRate":0.006701},{"month":11,"riseRate":0.695652,"avgChangeRate":0.018679},{"month":12,"riseRate":0.391304,"avgChangeRate":-0.026047}],"exchange":"NYSE","name":"Tri-Continental Corp","nameEN":"Tri-Continental Corporation"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tri-Continental Corp(TY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Tri-Continental Corp(TY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Tri-Continental Corp,TY,Tri-Continental Corp股票,Tri-Continental Corp股票老虎,Tri-Continental Corp股票老虎国际,Tri-Continental Corp行情,Tri-Continental Corp股票行情,Tri-Continental Corp股价,Tri-Continental Corp股市,Tri-Continental Corp股票价格,Tri-Continental Corp股票交易,Tri-Continental Corp股票购买,Tri-Continental Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tri-Continental Corp(TY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Tri-Continental Corp(TY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}